Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + lenvatinib + HAIC for initially unresectable cholangiocarcinoma
ChiCTR2600134241Phase 4Recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Nov 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab and lenvatinib in cholangiocarcinoma (CCA), sponsored by Shandong Cancer Hospital. Primary endpoint: Objective response rate. Started Nov 2025; status: recruiting.
02
Drugs
camrelizumablenvatinib
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on ChiCTR2600134241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600134241.